The stats show that even though the target for the two-week wait for suspected breast cancer has been met, more people than ever with suspected...

19 November 2014

Baroness Delyth Morgan, Chief Executive of Breast Cancer Campaign, said: “The report released today by Macmillan confirms how much there is...

14 November 2014

In response to yesterday's announcement that many breast cancer medicines including Perjeta Kadcyla and Eribulin are up for re-evaluation within...

13 November 2014

The Scottish Medicines Consortium has announced today that Pertuzumab (Perjeta) is not recommended for use within NHS Scotland for patients with...

10 November 2014

The Royal College of Obstetricians and Gynaecologists (RCOG) has published new patient information to provide information for women who are...

7 November 2014

Katherine Woods, Research Communications Manager at Breast Cancer Campaign, said: “Once breast cancer spreads throughout the body it becomes...

5 November 2014

In response to the news that two major trials involving more than 1800 women with secondary breast cancer found eribulin boosted survival by more...

3 November 2014

Mia Rosenblatt, Head of Policy and Campaigns at Breast Cancer Campaign said: “Eribulin was rejected by NICE for use on the NHS in April...

3 November 2014

Katherine Woods, Research Communications Manager at Breast Cancer Campaign, comments: “Pin-point tattoo marks created during radiotherapy are...

2 November 2014